Interim Analysis Expected End of 2Q 2025BETHESDA, MD, Mar 14, 2025 - (ACN Newswire) - Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading ...
Longeveron (LGVN) announced the publication in Nature Medicine of results from the CLEAR MIND Phase 2a clinical trial evaluating laromestrocel ...
We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...
The Phase 2b ICONA clinical trial was a 52-week randomized, double-blind, placebo-controlled trial that evaluated the safety and histological impact of icosabutate at 300 and 600 mg compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback